Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
AUTOR(ES)
Goldstein, B P
RESUMO
MDL 63,246 is a semisynthetic derivative of the naturally occurring glycopeptide antibiotic MDL 62,476 (A40926). It was more active in vitro against Staphylococcus aureus and coagulase-negative staphylococci than MDL 62,476, teicoplanin, and vancomycin and was more active than mideplanin (MDL 62,873) against some isolates. MDL 63,246 had excellent activity against streptococci and teicoplanin-susceptible enterococci, and it also had in vitro activity against some VanA enterococcal isolates. It was more active than teicoplanin and vancomycin against acute staphylococcal, streptococcal, and enterococcal septicemia in immunocompetent and neutropenic mice. It was highly efficacious in reducing the bacterial load in the hearts of rats in staphylococcal endocarditis experiments and the bacterial load of Staphylococcus epidermis in a high infection model in neutropenic mice. The excellent in vivo activity of MDL 63,246 appears to correlate both with its in vitro antibacterial activity and with its long half-life in rodents.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162785Documentos Relacionados
- Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat.
- In vitro activity of the semisynthetic glycopeptide amide MDL 63,246.
- In vitro activity of SK&F 104662, a new glycopeptide antibiotic.
- In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.
- Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic.
